XERS
Xeris Biopharma Holdings, Inc. Health Care Pharmaceutical Preparations Russell 3000
$10.71Close
$1.8BMarket cap
$5.29 – $11.1352-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 89 · stronger than 89% of stocks over 12 months
- Near its high 4% below its 52-week high
- Accumulation up-day volume 1.8× down-day volume over 50 sessions
Cautions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
up 5.0%
price change
1mo
up 12.0%
price change
12-month return
up 10%
market up 11% ·
its own 0%
F-score
—
— Not assessed
Altman Z
1.82
Moderate risk
P/E
3213.3×
price / earnings
PEG
—
P/E / EPS growth
P/B
130.0×
price / book
Earnings yield
up 1.3%
EBIT / enterprise value
Cheaper than
22%
of the market · expensive
Revenue growth
up 44%
year on year
EPS growth
—
latest quarter
Sales growth
up 29%
latest quarter · -10 pts
ROE
up 4%
return on equity
Free cash margin
up 10%
$28.6M FCF
D/E
16.10
long-term debt / equity
Net debt / EBITDA
4.2×
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- FCF turned positive ($-37M → $29M)
Trade setup
ATR%
4.4%
$0.48 a day · 2×ATR $9.76
RS
89 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
1.77
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Heavily indebted Net debt is 4.2 times EBITDA — roughly 4 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Shareholders diluted The share count rose 11.2% over the year, from 149m to 166m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-3% vs market2 sessions after results
Financials
- Net 0%
- Free cash 10%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $20.2M | $49.6M | $110.2M | $163.9M | $203.1M | $291.8M |
| Operating income | -$83.5M | -$115.2M | -$81.9M | -$44.0M | -$33.6M | $24.9M |
| Net income | -$91.1M | -$122.7M | -$94.7M | -$62.3M | -$54.8M | $554,000 |
| Net margin | -452% | -247% | -86% | -38% | -27% | 0% |
| Earnings per share | — | -$1.55 | -$0.70 | -$0.45 | -$0.37 | $0.00 |
| Free cash flow | -$80.9M | -$96.6M | -$102.9M | -$47.0M | -$37.0M | $28.6M |
| Free cash margin | -402% | -195% | -93% | -29% | -18% | 10% |
| Cash | $37.6M | $67.3M | $122.0M | $67.4M | $71.6M | $111.0M |
| Long-term debt | $87.0M | $88.1M | $187.1M | $190.9M | $217.0M | $220.3M |
| Shareholders' equity | $33.8M | $95.2M | $45.2M | -$6.8M | -$29.6M | $13.7M |
| Shares outstanding | 59.61m | 124.87m | 136.27m | 138.13m | 149.43m | 166.22m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 6, 2025 | Annual ↗ | Dec 31, 2024 | 65d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 6, 2024 | Annual ↗ | Dec 31, 2023 | 66d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 14, 2026 | Other events ↗ |
| Sep 9, 2026 | Regulation FD ↗ |
| Aug 6, 2026 | Results ↗ |
| Jul 17, 2026 | Unregistered share sale · Other events ↗ |
| Jun 30, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 11, 2026 | Unregistered share sale · Other events ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 21, 2026 | Director or officer change ↗ |
| Mar 2, 2026 | Results ↗ |
| Feb 27, 2026 | Regulation FD ↗ |
| Jan 8, 2026 | Results ↗ |